Cargando…
Biosimilars Adoption: Recognizing and Removing the RoadBlocks
Almost two decades since biosimilars arrived, we still await their broader adoption, as anticipated. The roadblocks to this adoption include the high amortized cost of goods due to regulatory burden, hurdles created by the distribution system, perception of safety and efficacy, and lack of focus by...
Autor principal: | Niazi, Sarfaraz K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106314/ https://www.ncbi.nlm.nih.gov/pubmed/37077364 http://dx.doi.org/10.2147/CEOR.S404175 |
Ejemplares similares
-
Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars
por: Niazi, Sarfaraz
Publicado: (2022) -
Molecular Biosimilarity—An AI-Driven Paradigm Shift
por: Niazi, Sarfaraz K.
Publicado: (2022) -
Overcoming the translational roadblocks: a cancer care and research model
por: Braun, Lauren, et al.
Publicado: (2014) -
No two classes of biosimilars: Urgent advice to the US Congress and the FDA
por: Niazi, Sarfaraz K.
Publicado: (2022) -
The Inflation Reduction Act: A boon for the generic and biosimilar industry
por: Niazi, Sarfaraz K.
Publicado: (2022)